1 TITLE: Clinical and Economic impact of updated Fall 2023 COVID-19 vaccines in the 2 Immunocompromised Population in Canada

3

- 4 Authors: Amy Lee,¹ Kavisha Jayasundara,² Michele Kohli,¹ Michael Maschio,¹ Kelly Fust,¹ Keya
- 5 Joshi,³ Nicolas van de Velde,³ and Ekkehard Beck³
- ⁶ ¹Quadrant Health Economics Inc; 92 Cottonwood Cresent, Cambridge, Ontario, Canada
- ⁷²Moderna BioPharma Canada, Suite 1700, Park Place, 666 Burrard Street, Vancouver, BC,

8 Canada

- ³Moderna Inc; 200 Technology Square, Cambridge, MA, United States
- 10
- 11 Corresponding author
- 12 Amy Lee, PhD; Quadrant Health Economics Inc; 92 Cottonwood Crescent,
- 13 Cambridge, ON N1T 2J1, Canada

14 **ABSTRACT**

Background: Immunocompromised (IC) individuals are at increased risk of COVID-19 infectionrelated severe outcomes. Moderna and Pfizer-BioNTech COVID-19 mRNA vaccines are available
in Canada, and differences in vaccine effectiveness (VE) have been found between the two in IC
individuals. The objective of this analysis was to compare the clinical and economic impact of a
Moderna XBB.1.5 updated COVID-19 mRNA Fall 2023 vaccine to a Pfizer-BioNTech XBB.1.5
updated COVID-19 mRNA Fall 2023 vaccine in Canadian IC individuals aged ≥18 years.

21 Methods: A static decision-analytic model estimated the number of COVID-19 infections, 22 hospitalizations, deaths, and resulting quality-adjusted life years (QALYs) over a one-year time 23 horizon (September 2023-August 2024) in the Canadian IC adult population (n=894,580). Costs 24 associated with COVID-19 infection were estimated from health care and societal perspectives. 25 The predicted VE of the updated Moderna vaccine was based on prior variant versions, which 26 were well-matched to the circulating variant. Pfizer-BioNTech VE was calculated based on a 27 meta-analysis of comparative effectiveness between both vaccines (relative risk for Moderna 28 vaccine: infection=0.85 [95%CI 0.75-0.97], hospitalization=0.88 [95%CI 0.79-0.97]). The model 29 combined VE estimates with COVID-19 incidence and probability of COVID-19 related severe 30 outcomes. Sensitivity analyses tested the impact of uncertainty surrounding incidence, 31 hospitalization and mortality rates, costs, and QALYs.

Results: Given the expected higher VE against infection and hospitalizations with the Moderna Fall 2023 vaccine, its use is predicted to prevent an additional 2,411 infections (3.6%), 275 hospitalizations (3.7%), and 47 deaths (4.0%) compared to the Pfizer-BioNTech Fall 2023 vaccine, resulting in 330 QALYs gained, and savings of \$7.4M in infection treatment costs, and \$0.9M in productivity loss costs. Results were most sensitive to variations in VE parameters, 37 specifically the relative risk of infection and hospitalizations between the vaccines, and waning38 rates.

39 Conclusions: If the Moderna and Pfizer-BioNTech Fall 2023 vaccines protect against infection 40 and hospitalizations similar to previous vaccines, using the Moderna Fall 2023 vaccine would 41 result in substantial public health benefits in IC individuals, as well as provide health care and 42 societal cost savings.

43

Keywords: coronavirus vaccine, economic modeling, decision analysis, coronavirus
hospitalization, vaccine effectiveness, Canada

46 **INTRODUCTION**

On May 5, 2023, the World Health Organization (WHO) declared that COVID-19 is no longer considered a public health emergency, but an ongoing health issue.¹ It recommended that vaccination efforts continue, particularly in high-priority groups. As the SARS-CoV-2 virus continues to evolve, there is an emphasis on updating the vaccines to target the current variants of concern. On September 12, 2023, the Canadian National Advisory Committee on Immunization (NACI) amended their guidance on the use of COVID-19 vaccines in the Fall of 2023.²

53 The updated Canadian guidance advises the use of an XBB.1.5-containing COVID-19 vaccine, 54 with particular importance placed on those at increased risk of COVID-19 severe disease, such 55 as those with underlying medical conditions, including those with primary immunodeficiency 56 diseases, malignancies or who use immunosuppressive medications.³

57 Compromised immune systems can be due to genetic defects or conditions that suppress the 58 immune system,⁴ such as solid tumours or hematologic malignancies, solid organ or 59 hematopoietic stem cell transplants, chronic kidney disease on dialysis, human immunodeficiency 60 virus (HIV), and chronic use of immunosuppressive or immunomodulatory medications.⁵ These 61 individuals are considered to be moderately to severely immunocompromised by the Canadian 62 National Advisory Committee on Immunization (NACI),⁵ and are at greater risk of hospitalizations. and mortality from infectious diseases, including COVID-19.46-9 It is therefore important to 63 increase their immune response against SARS-CoV-2 through vaccination. 64

The protective response mounted by immunocompromised (IC) individuals to the COVID-19 vaccinations is decreased compared to their immunocompetent counterparts. In a prospective cohort study conducted at Kaiser Permanente Southern California, Tseng et al., (2023) found the adjusted vaccine effectiveness (VE) for the general population of the Moderna BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against hospitalization was 82.8%, but reduced to 71.8% in those that

were IC.¹⁰ Additionally, similar to the general population,¹¹⁻¹⁵ VE has been found to differ between 70 71 the two mRNA COVID-19 vaccines in the IC population. Although both Moderna and Pfizer-72 BioNTech COVID-19 vaccines utilize mRNA technology, the formulation, including the type of nanoparticles used for the mRNA delivery system, and dosage of each vaccine differ.¹⁶⁻¹⁹ A 73 74 systematic literature review and meta-analysis based on 17 studies by Wang et al., (2023) found 75 that in the IC population, the Moderna mRNA-1273 vaccine to be associated with significantly 76 lower risk of COVID-19 infection, hospitalizations, and deaths compared to the Pfizer-BioNTech BNT162b2 vaccine (relative risk for infection = 0.85 [95% CI 0.75-0.97]; hospitalization = 0.88 77 [95% CI 0.79-0.97]).²⁰ 78

79 Given the approval of the recently updated COVID-19 vaccines in Canada for both Moderna and 80 Pfizer-BioNTech,^{21,22} the question arises on whether and to which extend there may be clinical or 81 economic differences between the use of these two mRNA vaccines in this vulnerable IC 82 population. The objective of this analysis was to estimate the clinical and economic impact of a 83 Moderna XBB.1.5 updated COVID-19 mRNA Fall 2023 vaccine (Moderna Fall 2023 vaccine) 84 compared to a Pfizer-BioNTech XBB.1.5 updated COVID-19 mRNA Fall 2023 vaccine (Pfizer-BioNTech Fall 2023 vaccine) in IC individuals aged 18 years over a one-year time horizon from 85 September 2023 to August 2024. 86

87

88 METHODS

89 Overview

A static decision analytic model was developed in Microsoft Excel to estimate the number of infections, hospitalizations, deaths, and costs associated with COVID-19 treatment over the course of one year (September 2023-August 2024) for the Canadian population. The model combined estimates of the incidence of COVID-19 in Canada, the effectiveness of updated 94 COVID-19 vaccinations and the probability of severe outcomes from COVID-19 infections. The
95 economic costs were estimated from both health care system and societal perspectives.
96 Outcomes estimated included the number of COVID-19 infections, hospitalization and deaths as
97 well as associated quality-adjusted life-years (QALYs) and costs.

98 The target population of this analysis was moderately to severely IC individuals in Canada aged
 99 ≥18 years considered to be at increased risk of severe disease from COVID-19 as defined by the
 100 National Advisory Committee on Immunization (NACI).²³

101 A Markov model with tunnel states was used to track the monthly COVID-19 vaccination status 102 of the target population, over a one-year analytic time horizon. At the start of the time horizon 103 (September 2023), the 2023 Canadian IC population aged ≥18 years was assigned to the 104 following historical vaccine coverage strata based on the highest level of prior COVID-19 vaccine 105 received: did not receive primary series; received primary series; received first booster; received 106 second booster. For historical vaccination coverage in the IC population, 3 doses (2 doses for 107 Ad26.COV2.S) were considered primary series.⁵ Additional doses were considered boosters. 108 Data on COVID-19 vaccine coverage in the IC population up to August 13, 2023 were obtained 109 from the Institute for Clinical Evaluative Sciences (ICES), which provided number of individuals in priority groups vaccinated by dose, and risk conditions.²⁴ Risk conditions that matched the 110 111 Canadian Immunization Guide COVID-19 vaccine's criteria for moderate/severe IC were 112 included.⁵ The percentage of the IC population by age (18-59 years, ≥ 60 years) that received 113 primary series, 1 booster, or 2 boosters as their highest level of vaccination was calculated by 114 dividing the total number of IC individuals that received each level of vaccination by the total 115 number of IC individuals. The distribution of individuals, by age, and vaccination strata, are 116 displayed in Table 1.

117 Table 1. Historical coverage in immunocompromised individuals, by highest level of

Age	Did not receive	Received	Received first	Received
	primary series	primary series	booster	second booster
		only		
18-59 years	41.9%	32.9%	17.9%	7.3%
60+ years	14.7%	21.2%	23.0%	41.1%

vaccination and age

119

118

Individuals who had completed at least primary series vaccination were able to move to the Fall 2023 vaccination strata. The model simulation was run twice: once where those in the Fall 2023 vaccination strata receiving the Moderna Fall 20203 vaccine and once where they receive the Pfizer-BioNTech Fall 2023 vaccine. The outcomes from each model run were compared.

124 The maximum Fall 2023 uptake was age-group specific and assumed to be the same as that 125 achieved by the general Canadian population for the COVID-19 second booster, as these were the most complete data available.²⁵ Roll-out of the second booster was extremely staggered, 126 127 given timing of the second booster and 6 month recommended time interval between doses, therefore uptake patterns from a shorter vaccine campaign was needed. Uptake was assumed to 128 129 occur over five months (September 2023-January 2024), as observed during the 2021-2022 seasonal influenza vaccination campaign.²⁶ Furthermore, the proportion of the total COVID-19 130 131 vaccinations that were administered each month was based on the monthly uptake rates observed during the 2021-2022 influenza campaign.²⁶ The final uptake pattern by month and age 132 133 is displayed in Figure 1. Individuals receiving the Fall 2023 vaccine are drawn from each 134 vaccination strata proportionally. Optimistic scenario analyses were included where the uptake in

- the 80+ years age group was increased from 73% to 80% (increase of 9%) and 95% (increase of
- 136 30%), with all other age group values adjusted up by the same multiplier.

137 Figure 1. Fall 2023 COVID-19 vaccine uptake, by age group.



Fall 2023 Vaccine Uptake

138

139 The cohort begins the model in the Well health state (Figure 2). Each month, individuals are at 140 risk of COVID-19 symptomatic infection, which is dependent on infection incidence. The risk is 141 decreased by prior vaccination status, as well as whether they received the Fall 2023 vaccine. If 142 the individual develops a COVID-19 symptomatic infection, they move through an infection 143 consequence decision tree (Figure 3, described in detail further below), which calculates 144 subsequent costs and clinical outcomes of infection. Those with infections can remain in the 145 Well health state (shown as Recovered in the consequence decision tree), or transition to the 146 Dead health state (shown as In-Hospital Mortality in the decision tree). Death in the model is only due to COVID-19 due to the short time horizon. All-cause mortality is not included. 147

149 Figure 2. Model structure



152 ^b death due to COVID-19

153 Figure 3. Infection consequence decision tree structure



- 155 *risk of inpatient care dependent on vaccination status
- 156 ICU, intensive care unit
- 157

154

159 **Population size**

An IC population size of 894,580 was included in the analysis. This was estimated, by age group, based on a US-based survey to determine the prevalence of immunocompromised individuals,²⁷ as well as a Statistics Canada survey conducted near the start of the COVID-19 pandemic to determine the breakdown of the population by age.²⁸ Further details are provided in the Supplementary Material.

165

166 Incidence

As the true incidence of COVID-19 infection in Canada is underestimated due to the lack of mandatory testing and reporting, the infection incidence was calculated using Public Health Agency of Canada (PHAC) COVID-19 hospitalization data for the general population for September 2022 to August 2023.²⁹ Data collection for July and August 2023 were incomplete and therefore, the ratio of the rates from June 2022 to June 2023 was applied to the rates from July and August 2022 to approximate the hospitalization rates for July and August 2023.

The symptomatic infection incidence required to result in the predicted monthly rate of hospitalizations was then back-calculated. To do this, calibration was performed using a version of the Markov model populated with general population data, with the calibration target set to the expected number of COVID-19 hospitalization data based on the data from PHAC. This method estimated the monthly symptomatic infection incidence for September 2022 to August 2023. In the base case analysis, it was then assumed that the COVID-19 incidence was the same for September 2023-August 2024 as the prior year.

The projected monthly incidence rates of COVID-19 infection for September 2023-August 2024
and additional details are provided in the Supplementary Material.

182 **Residual vaccine effectiveness**

183 Residual VE is necessary to estimate the level of protection in the population entering the model 184 at the start of the analytic time horizon (September 1, 2023) due to prior vaccinations. This is 185 calculated using the timing of the prior boosters, VE of primary series and boosters against the 186 dominant variant at time of administration, and the historical coverage in the IC population.

187 The VE of primary series and monovalent boosters against Omicron BA.1/BA.2 for infection and 188 hospitalizations in the general population were obtained from the meta-analysis by Pratama et al. (2022).³⁰ As there is a mix of primary series vaccines, the VE estimates for all vaccines were 189 190 used. For the VE of booster vaccination, results for mRNA vaccines were used. Primary and 191 booster monovalent VE against hospitalizations were further adjusted to account for the reduced 192 VE observed in the IC population and due to the emergence of BA.4/5 by using the ratio between 193 monovalent against omicron in the general population, and bivalent against BA.4/BA.5 in the IC 194 population.

Bivalent boosters (assumed to be first booster for some, and second booster for all in the IC population) were available during the period of BA.4/5 dominance. The VE for bivalent boosters against hospitalization in the IC population was obtained from a Kaiser Permanente study of the Moderna bivalent vaccine (71.8%, 95% CI 48.8%-84.5%).¹⁰ As VE against infection was not available for the IC population, it was assumed to be equivalent to monovalent vaccine against Omicron (57.1% from Pratama et al., 2022^{30,31}) for the general population.

Monthly VE waning for primary series and boosters for both infection (4.8%) and hospitalization (1.4%) were assumed to be the same monovalent booster waning rates estimated in the metaanalysis by Higdon et al., (2022).³¹

Timing of prior boosters was obtained from coverage by week and age data from Public Health Ontario.³² The month when 50% of vaccine were administered for primary series (Dec 2021), first 206 booster (May 2022 for those who received monovalent booster. November 2022 for those who 207 received bivalent booster), and second booster (November 2022, bivalent) for the oldest age 208 group was used as a proxy for vaccine administration date for each level of vaccination (primary 209 series, boosters).³² The timing of vaccine administration differed among age groups but this 210 simplifying assumption was adopted because the older age groups had significantly higher prior 211 coverage levels compared to younger age groups. Some IC individuals received monovalent and 212 some received bivalent vaccines as their second booster. Due to the difference in VE between 213 these two vaccine types, and timing of when administered, the residual VE of both were 214 calculated, then weighed by proportion that received each (60% received monovalent, and 40% received bivalent as their second booster).³³ Those that received the second booster mainly 215 216 consisted of individuals aged 60+ that received a monovalent vaccine as their first booster earlier 217 in the year. It was assumed that the IC population completed the same level of vaccinations similar 218 to the general population, with the adjustment for the additional dose during primary series for the 219 IC population. The residual VE at start of the analytic time horizon is shown in Table 2.

220 Table 2. Residual vaccine effectiveness in the immunocompromised population at start

221

of analytic time horizon

	Infection	Severe
Completed primary series	0.0%	21.5%
Completed first booster	3.7%	53.2%
Completed second booster	9.3%	58.1%

222

224 Vaccine effectiveness of the Moderna and Pfizer-BioNTech Fall 2023 vaccines

225 Real world effectiveness on the Moderna and Pfizer-BioNTech Fall 2023 vaccines are not yet 226 available. Therefore, in the base case analysis, the vaccines are assumed to be well-matched to 227 the current variant, and are assumed to protect at the same level against the circulating dominant 228 variant as the bivalent booster (mRNA-1273.222 and BNT126b2 [WT/ OMI BA.4/BA.5]) protected 229 against BA.4/BA.5. Therefore, like the bivalent booster values used to calculate residual 230 effectiveness, the initial VE of the Moderna Fall 2023 vaccine was set to 71.8% for hospitalization 231 based on the Kaiser Permanente study of the Moderna bivalent vaccine,¹⁵ and 57.1% for infection, based on the estimate for monovalent vaccine against Omicron from Pratama et al.³⁰ To 232 233 approximate the VE of a well-matched Pfizer-BioNTech Fall 2023 vaccine, the relative risk of 234 hospitalization and infection in the IC population for the Moderna bivalent booster compared to 235 the Pfizer-BioNTech bivalent booster (relative risk [RR] = 0.88 and 0.85, respectively) from Wang et al., (2023) was applied to the assumed VEs for the Moderna Fall 2023 vaccine.²⁰ This resulted 236 237 in estimated initial VEs of 68.0% and 49.6%. The waning of the Fall 2023 vaccines were assumed 238 to be the same as the monovalent booster waning rates estimated in the meta-analysis by Higdon 239 et al., (2022).³¹ VE inputs for the base case and sensitivity analyses are summarized in Table 3.

240 Table 3. Base case and sensitivity analyses vaccine effectiveness inputs

Description of	Moderna Fall 2023 vaccine				Pfizer-BioNTech Fall 2023 vaccine				
analysis	Infection Hospit		Hospita	alization Infe		ction	Hospita	Hospitalization	
	Initial	Waning	Initial	Waning	Initial	Waning	Initial	Waning	
	VE		VE		VE		VE		
Base case analysis	57.1%	4.8%	71.8%	1.4%	49.6%	4.8%	68.0%	1.4%	
Sensitivity analysis:	30.6%,	Equal	48.8%,	Equal	18.3%,	Equal	41.8%,	Equal	
Moderna vaccine initial	83 7%	to base	84 5%	to base	80.8%	to base	82 4%	to base	
VE (95% CI)	0011 /0	case	0 110 / 0	case	00.070	case	02.170	case	
Sensitivity analysis:			L			Equal		Equal	
RR 95% CI (Moderna					42.8%,	to hope	64.3%,	to booo	
vs. Pfizer-BioNTech		Equal to t	Dase case		55.8%	to base	70.9%	to base	
vaccines) for initial VE						case		case	
Sensitivity analysis:	Equal		Equal		Equal		Equal		
Fall 2023 vaccine	to	3.1%,	to	0.6%,	to	3.1%,	to	0.6%,	
waning	base	6.8%	base	2.4%	base	6.8%	base	2.4%	
	case		case		case		case		
Sensitivity analysis:		L		L	Equal		Equal		
differential waning for	Equal to base case			to	E 69/	to	4.00%		
Moderna & Pfizer-				:	base	5.0%	base	1.0%	
BioNTech vaccines*					case		case		

241

*The monthly waning rate for the Pfizer-BioNTech vaccine was adjusted so that the relative risk of infection and

242 hospitalization between Moderna and Pfizer-BioNTech vaccines (0.85 and 0.88, respectively) was maintained for each

243 month of the time horizon.

244 VE: vaccine effectiveness; CI: confidence interval; RR: relative risk;

245 Infection consequences decision tree

The transition probabilities associated with the consequences of infection included in the infection consequence decision tree (Figure 3), are summarized in Table 4. Input data were obtained from targeted literature reviews and were estimated based on published sources, fee schedules, and databases. Where available, Canadian sources and data were used.

250 Infected individuals either require hospitalization (inpatient care), or they do not. To inform the 251 risk of hospitalization in those without protection from COVID-19 vaccination, the model requires 252 the risk of hospitalization given infection in the unvaccinated population. As current Canadian data 253 are not disaggregated by vaccination status, the age-specific risk of hospitalization given infection 254 from the pre-vaccination period (July-December 2020) was first used and calculated from PHAC data using number of infections and hospitalizations by age.³⁴ These data were then adjusted to 255 256 the omicron period using the RR (0.58) of hospitalization between the omicron and delta period from a study by Wang et al., (2022).³⁵ These age-specific risks of hospitalization during omicron 257 258 given infection were then further adjusted to the immunocompromised population using the RR 259 (1.94) of hospitalization between moderately and severely immunocompromised individuals and 260 those not considered at high risk of severe outcomes during omicron, using data from a Canadian 261 study by Bahremand et al (2023).⁹ Final model inputs are displayed in Table 4.

Hospitalization stay is categorized by the highest level of care required (general ward, ICU without
ventilation, ICU with ventilation). The distribution, by age, were obtained from September 2022August 2023 PHAC data.²⁹. Deaths were only assumed to occur in those requiring hospitalization.
Probabilities of death for the general population in those hospitalized, by age, were calculating by
dividing the number of deaths by the number of hospitalizations from 2022-23 PHAC data.³⁶
These values were increased in the IC population for all ages by applying the odds ratio for
mortality between immunocompromised and immunocompetent individuals from Turtle et al.

- 269 (2023).⁸ As data were not disaggregated by hospital location of care, probabilities were assumed
 270 to be the same for all.
- All individuals with COVID-19 infection are subject to a "post-infection" cost and disutility toll representing longer-term cost impacts. ³⁷ As the "post-infection" costs and disutility represented the average cost of all patients with a COVID-19 infection, it also included individuals who developed long COVID. Therefore, long COVID was not represented separately in the model.

276 Table 4. Base case infection consequences decision tree probabilities

	Hospitalization rates	Hospitalization loc	In-hospital		
Age group	(unvaccinated) given infection, by age (%) ^{9,34,35*}	No ICU or ventilation	ICU	ICU with ventilation	mortality rates, by age ^{8,36} †
18-19 years	0.5%	89.11%	5.41%	5.48%	1.08%
20-29 years	1.1%	91.81%	4.07%	4.12%	1.68%
30-39 years	2.1%	89.90%	5.02%	5.08%	2.56%
40-49 years	2.8%	86.32%	6.80%	6.88%	5.58%
50-59 years	4.9%	85.21%	7.35%	7.44%	6.98%
60-69 years	10.8%	86.51%	6.70%	6.79%	9.54%
70-79 years	24.8%	90.77%	4.59%	4.64%	12.19%
80+ years	30.1%	95.82%	2.08%	2.10%	20.64%

277

* Adjusted for Omicron³⁵ and immunocompromised status⁹

278 [†]Only applied to hospitalized patients

ICU: Intensive care unit

280

282 Resource use and costs

For the base case, resource use and costs associated with the treatment of infections and their consequences are considered. As coverage in both comparator arms are expected to be the same, and rates of adverse events are assumed to be similar and costs associated with adverse events are also excluded. Therefore, only resource use and costs incurred due to the treatment of COVID-19 infection (acute, post-infection, and from the societal perspective, productivity loss) are included. Acute infection resource use includes non-hospitalized (emergency department and physician visits) and hospitalizations due to acute infection.

Post-infection costs include ongoing care following the initial acute infection. Resource use was based on a Canadian retrospective database study on individuals' post COVID-19 test. The incremental resource use in those with positive tests were calculated by comparing use by those with negatives tests, starting 56 days post test, and represented a year of resource use.³⁷ Incremental resource use included hospitalization, outpatient medical encounters, home care, emergency department visits, and long-term care days. Costs for each resource were applied based on standard fee schedules.³⁷

All costs were inflated to 2022 Canadian dollars using Statistics Canada's Consumer Price Index.³⁸. Cost inputs from the health care perspective are displayed in Table 5. Societal cost inputs are provided in the Supplementary Material.

301 Table 5. Cost inputs

Model parameter	Value	Assumptions
Short-term infection: non-hospitalized	\$111	Cost per outpatient visit ³⁹ and emergency department visits, ^{39,40} adjusted for average number of outpatient visit (0.34) and emergency department visit (0.25) per infection. ⁴¹
Hospitalization (per stay)		
No ICU or ventilation	\$19,484	Average cost April 2022-September
ICU	\$54,672	- 2022. ⁴²
ICU with ventilation	\$54,672	- Cost for ICU with ventilation stay assumed same as ICU stay as data source did not differentiate the two.
Post-Infection	\$513	Reported resource use, including average number of outpatient visits, hospitalization days, and long-term care days. ^{37-39,43} Not disaggregated by hospital status.
Quality-Adjusted Life-Years Lost		
Symptomatic infection, not hospitalized ^{44,45}	0.003	Applied to all symptomatic infections regardless of whether they were medically-attended or not.
Hospitalized, general ward ^{46,47}	0.008	The symptomatic infection, not hospitalized
Hospitalized, ICU (no ventilator) ^{46,47}	0.016	decrement is also added to the hospitalized

Hospitalized, ICU with ventilator ^{46,47}	0.030	values	to	reflect	symptoms	prior	to
		hospita	lizat	on			
	0.0077						
Post-infection, not nospitalized**	0.0277						
Post-infection, hospitalized ⁴⁹	0.122						

302

ICU: Intensive care unit; QALY: quality-adjusted life-year

303

304 Quality-adjusted life-years

Infections, hospitalizations, post-infections, and death are all associated with quality-adjusted lifeyear (QALY) decrements. The impact of the morbidity associated with COVID-19 infections is captured as the QALY decrements provided in Table 5.The estimated number of life-years lost due to premature COVID-19 mortality was calculated using the most recent Statistics Canada data on life expectancy by age.⁵⁰ This was multiplied by the Canadian average population values for QALYs experienced by age.⁵¹ All future QALYs were discounted to present value at rate of 1.5%.⁵²

312 Scenario analyses and deterministic sensitivity analyses

In addition to the scenario and sensitivity analyses previously mentioned, analyses were conducted on incidence, hospitalization and mortality rates, costs, and QALY decrements. Where available, lower and upper 95% confidence intervals were used. All other values were varied by $\pm 25\%$. Value used for the included sensitivity analyses are presented in the Supplementary Material.

318

320 RESULTS

321 In the base case analysis, assuming an IC population size of 894,580, there is expected to be 322 65,536 symptomatic infections, 7,151 hospitalizations and 1,133 deaths when vaccinating the 323 Canadian IC adult population with the Moderna Fall 2023 vaccine from September 2023 - August 324 2024. This was achieved with 359,067 vaccinations administered between September 2023-325 January 2024. Given the expected lower VE of the Pfizer-BioNTech vaccine, the Moderna vaccine 326 is expected to prevent 2,411 infections (3.5%), 275 hospitalizations (3.7%), and 47 deaths (4.0%) 327 compared to vaccinating with Pfizer-BioNTech. Additionally, 330 more QALYs would be gained 328 with the Moderna Fall 2023 vaccine, with over half being attributed to the prevention of death 329 (Table 6). From the health care perspective, the prevented infections and hospitalizations with 330 use of the Moderna Fall 2023 vaccine results in a \$7.4 million saved in treatment costs; when 331 productivity losses are included, \$8.3 million in treatment cost savings are realized.

333 Table 6. Base case results

	Moderna Fall 2023	Pfizer-BioNTech	Difference*	
	vaccine	Fall 2023 vaccine		
	Clinical Outcomes			
Number of vaccinations	359,067	359,067	0	
Cases				
Symptomatic infections	65,585	67,996	-2,411	
Hospitalizations	7,151	7,426	-275	
COVID-19 related deaths	1,133	1,180	-47	
QALYs lost				
Morbidity	2,587	2,682	-96	
Mortality	6,457	6,692	-235	
Total QALYS lost	9,044	9,374	-330	
	Economic Outcomes			
Short-term infection costs	\$164,397,246	\$170,630,436	-\$6,233,190	
Post-infection period	\$33,054,168	\$34,266,464	-\$1,212,296	
Total Health care perspective	\$197,451,414	\$204,896,900	-\$7,445,486	
Productivity loss	\$39,488,494	\$40,338,892	-\$850,397	
Total societal perspective	\$236,939,908	\$245,235,792	-\$8,295,884	

334

*Moderna Fall 2023 vaccine- Pfizer-BioNTech Fall 2023 vaccine

335 QALY: quality-adjusted life-year

336

Results from scenario analyses on incidence and vaccine uptake continued to find treatment cost
savings and QALYs saved with the Moderna Fall 2023 vaccine compared to the Pfizer-BioNTech
vaccine. When the incidence of COVID-19 infection was increased or decreased, the difference
between the Moderna and Pfizer-BioNTech Fall vaccines for outcomes were increased or

341 decreased by the same percentage. Increasing the Fall 2023 vaccine uptake in those aged 80 342 years and older to 80% increased costs saved and QALYs gained by the Moderna Fall vaccine 343 compared to the Pfizer-BioNTech version by 9%, and increasing the uptake to 95% increased the 344 costs saved and QALYs gained by 30%, as more IC individuals are vaccinated, and therefore 345 contributing to the predicted benefits. Sensitivity analyses are presented in Figure 4. Tornado 346 diagrams summarizing the sensitivity analyses for both costs saved and QALYs gained with the 347 Moderna Fall vaccine compared to the Pfizer-BioNTech Fall vaccine are displayed. For ease of 348 comparison, parameters for both diagrams are listed in decreasing order according to differences 349 in cost saved. Parameters that did not have an impact on outcomes were excluded from the 350 diagrams. In the base case, the starting VE against infection and hospitalization for Pfizer-BioNTech were calculated using the Wang et al. RRs,²⁰ and the same waning rates were then 351 352 applied to both vaccines. Costs and QALYs were most sensitivity to changes where the RR of 353 infection and hospitalization was maintained between both vaccines for the entire analytic time 354 horizon, by adjusting the waning rate of Moderna and Pfizer-BioNTech vaccines upward. This 355 resulted in faster waning rates for the Pfizer-BioNTech vaccine. Next, model outcomes were 356 sensitivity to the RR for infection and hospitalizations between the vaccines, with higher RRs 357 resulting in lower costs and QALYs saved, and vice versa. The Moderna Fall vaccine initial VE 358 was also a driver of costs and QALYs, with higher initial VEs resulting in smaller VE differences 359 between the vaccines, and therefore a smaller difference in outcomes.

Figure 4. Sensitivity analyses tornado diagrams: cost and QALYs



CI: confidence interval; UB: upper bound; LB: lower bound; RR: relative risk; ICU: intensive care unit; QALY: quality-

```
366
         adjusted life-year
```

369 **DISCUSSION**

370 This study estimated the difference in number of infections, hospitalization and death in the 371 Canadian IC population over a one-year time horizon, with Moderna updated Fall 2023 vaccine 372 administration compared to Pfizer-BioNTech updated Fall 2023 vaccine administration. Given the 373 higher predicted VE of the Moderna Fall 2023 vaccine compared to the Pfizer-BioNTech vaccine, 374 in a population size of 894,580 IC adults, vaccinating with the Moderna vaccine is predicted to 375 prevent an additional 2,411 infections, 275 hospitalizations and 47 deaths, resulting in \$7.4 million 376 in health care cost savings, while gaining 330 QALYs. If productivity loss is included, the cost 377 saving could be \$8.3 million over the one-year time horizon.

The model is a simplification of the effects of vaccination on a population. It only accounts for direct protection of those receiving the vaccine, and only included the population of interest. It does not account for indirect protection through decreasing transmission in the general population. However, as the IC population is only a small sub-set of the entire Canadian population, vaccinating these individuals is unlikely to impact transmission in the general population.^{53,54}

384 The SARS-CoV-2 virus is constantly evolving, and there is high uncertainty around future variants 385 and incidence, and how responsive vaccines will be. Furthermore, as in many countries, many 386 individuals no longer seek a medical diagnosis for their symptoms and there is under-reporting of 387 COVID-19 infections in Canada. However, using the most recent information available on 388 hospitalizations, we predicted the possible infection incidence for September 2022 to August 389 2023. We assumed that the incidence of infection for September 2023 to August 2024 will be the 390 same as the previous year, however, it is impossible to know how COVID-19 will behave in this 391 new post-pandemic era. The incidence of COVID-19 infection was calculated from the general 392 population. While the IC population is at higher risk for more severe outcomes if they develop an

infection, it is not known if the incidence of infection is different from the general population. As
static models are linear by definition, a linear impact is seen on many parameters. For example,
in the scenario analyses where incidence was increased/decreased by 25%, differences between
the arms for costs saved and QALYs gained also increased/decreased by 25%.

397 Model results are highly sensitive to VE values of the Moderna and Pfizer-BioNTech Fall vaccines. 398 While it is true that the VE values used in this analysis are assumptions and not based on real 399 world data of the current XBB1.5 version of the vaccine, robust immunological response are 400 induced by the vaccines and were in the same magnitude of increase compared to previous 401 formulations against the intended variants.⁵⁵ Therefore, the estimate of the Fall 2023 vaccines 402 are based on real world data on previous versions of each vaccine. Despite the overall median 403 follow-up duration of 2.46 months, VE estimates against hospitalization from Tseng et al., (2023) 404 were used as it provided Moderna vaccine specific estimates during the time of BA.4/BA.5 dominance. This is in alignment with other modeling approaches.⁵⁶ Previous studies have found 405 higher VE values with Moderna vaccines compared to the Pfizer-BioNTech counterpart, 11-15,20 406 407 including in other vulnerable populations, such as residents in nursing and retirement homes.⁵⁷ 408 The data used in this analysis to estimate Pfizer-BioNTech Fall 2023 vaccine VEs were obtained 409 from a meta-analysis, which is considered the highest level of evidence in evidence-based medicine.⁵⁸ Difference in the VEs between the vaccines may be due in part to different 410 formulation, dosage, and delivery system.²⁰ In their Communicable Disease Control Manual, The 411 412 British Columbia Centre for Disease Control lists the Moderna Fall 2023 vaccine as the preferred 413 vaccine over the Pfizer-BioNTech version for IC individuals due to its potentially greater immune 414 response,⁹ which is correlated with VE.^{59,60} If we expect similar VE outcomes as in previous 415 version of the vaccine, then we can expect fewer infections, hospitalizations and deaths and lower 416 COVID-19 treatment costs with the Moderna updated Fall 2023 vaccine.

417 Although there are study limitations due the lack of IC specific data, steps have been taken to 418 adjust existing general population data, and determine the impact of uncertainty. Because data 419 were unavailable on the VE against infection of prior Moderna formulations in the IC population, 420 or on the relative VE for the general population compared to the IC population, we were unable 421 to estimate the adjusted VE against infection for the Moderna updated Fall 2023 vaccine from the 422 same source used to estimate the VE against hospitalization, and assumed the same VE against infection as mRNA-1273 against BA.1/BA.2 in the general population.³⁰ Although different 423 424 populations and time periods were used, the VE estimate against infection is conservative. If the 425 VE of the Moderna updated Fall 2023 vaccine against infection was assumed to be lower in the 426 IC population, then the estimated number of infections prevented compared to the Pfizer-427 BioNTech vaccine would be even larger (see Supplementary Material for results).

The population size was estimated using proportion estimated from the US, as suitable data were not available from Canada. Over or underestimating the population size will result in the total costs saved and QALYs gained to be over or underestimated, respectively.

Additionally, monthly VE waning rates were obtained from the general population. A study by Ferdinand et al. (2022), reported higher hospitalization waning rates over a six-month period in IC individuals during Delta/Omicron predominance.⁶¹ However, increasing the waning rates in sensitivity analysis had minimal effects on cost and QALYs as the waning rate was the same for both the Moderna and Pfizer-BioNTech Fall 2023 vaccines.

Although hospitalization and mortality rates were used for the Canadian general population, efforts were made to adjust these to the IC population by applying the increased risk observed in the IC population compared to immunocompetent individuals. In all sensitivity analyses surrounding these parameters, the Moderna Fall 2023 vaccine continued to result in cost savings and QALYs gained compared to the Pfizer-BioNTech Fall vaccine. Additionally, QALYs related to 441 COVID-19 infection and hospitalizations were based on the general population, and were not 442 adjusted due to lack of data. However, varying these values in sensitivity analyses had minimal 443 impact on total QALYs gained.

444 The proportion of hospitalized IC individuals that required ICU admission was based on the 445 general population data as Canadian data on the IC population was not available. However, a UK 446 study by Evans et al., (2023) found the 2.8-4.7% of hospitalized IC individuals in 2022 required 447 ICU admission compared to 2.1% overall. Based on PHAC data, the age-dependent rate of ICU 448 admission given hospitalizations in the general population between July 2022-August 2023 449 ranged from 4.2%-10.9%. Although the UK and Canadian populations included are not 450 comparable, the UK study suggests that there may be a higher proportion of ICU admissions in 451 hospitalized patients compared to the general population. As such, given that the Moderna Fall 452 2023 vaccine is predicted to result in fewer hospitalization compared to the Pfizer-BioNTech Fall 453 2023 vaccine, the cost savings and QALYs estimated by the current study is likely to be 454 underestimated.

455 Likewise, resource use and costs included in the analyses were obtained from the general 456 population, and not IC individuals, resulting in conservative estimates. Preliminary findings 457 comparing the two populations found that in the US, IC individual COVID-19 inpatient expenditures were 1.4 times greater than non-IC individuals.⁶² If healthcare expenditures up to 458 459 60 days post discharge were included, this value increases to 1.8 times greater. While the US 460 and Canadian health care systems and costing are not comparable, this study provides evidence 461 that IC individuals may require a higher volume of health care, and that the cost inputs used in 462 the current analysis may therefore be underestimated. Increasing these cost inputs would 463 increase the cost savings by the Moderna Fall 2023 vaccine compared to the Pfizer-BioNTech 464 vaccine, as confirmed in the cost sensitivity analyses. Therefore, the limitations in resource use

and cost values used in the base case result in extremely conservative estimates of the costssaved by use of the Moderna Fall 2023 vaccine.

467 Various other sensitivity analyses were conducted on the VE estimates, including the difference 468 in VE between the vaccines, and varying the monthly waning rate. Still, in every analysis, overall 469 results remained the same, with the Moderna Fall 2023 vaccine saving costs and gaining QALYs 470 compared to the Pfizer-BioNTech Fall 2023 vaccine. Cost savings varied from \$1.6 million, where 471 the relative risk of infection or hospitalizations between the two vaccines was closer to 1, resulting 472 in a smaller difference in VE values, to \$28.1 million, when the waning rate of Pfizer-BioNTech 473 was set higher. QALYs gained ranged from 71 to 1,227 (resulting from same sensitivity analyses 474 mentioned for cost savings). These findings were largely driven by the changes in the number of 475 hospitalizations.

476 The model only allowed those who completed primary series vaccination to receive a Fall 2023 477 vaccine, as was the case for the bivalent booster. The current NACI guidelines recommend the 478 XBB.1.5-containing formulations for those previously vaccinated. As the vaccines are also 479 authorized by Health Canada for those not previously vaccinated, NACI states that they may be 480 used to initiate primary series. However, recommendations for this population will be forthcoming 481 in the next months.² Additionally, as the historical ICES database coverage data from ICES found that only 15% of IC individuals aged 60 and above did not complete primary series,²⁴ it is unlikely 482 483 that vaccination of a small proportion of individuals with primary series would change model 484 results. Saskatchewan has indicated that moderately to severely IC individuals who have not 485 received primary series be vaccinated with multiple doses of the Fall 2023 vaccines, with 486 immunocompetent individuals requiring one.63

In conclusion, this study conservatively estimated the potential benefits of vaccinating the
Canadian IC adult population with the Moderna updated Fall 2023 vaccine instead of the Pfizer-

BioNTech Fall 2023 vaccine. If the Moderna and Pfizer-BioNTech Fall 2023 vaccines are wellmatched to the dominant variants and protect against infection and hospitalizations similar to previous versions of the vaccines, using the Moderna Fall 20203 vaccine could result in substantial health care and societal cost savings, as well as QALYs gained.

493 **REFERENCES**

- World Health Organization (WHO). Statement on the fifteenth meeting of the IHR (2005)
 Emergency Committee on the COVID-19 pandemic. Updated May 5, 2023. Accessed
 October 2, 2023.
- 498 2. National Advisory Committee on Immunization (NACI). An Advisory Committee Statement
 499 (ACS). Addendum on the guidance on the use of COVID-19 vaccines in the fall of 2023.
- 500 September 12, 2023. <u>https://www.canada.ca/content/dam/phac-</u>
- 501 aspc/documents/services/publications/vaccines-immunization/national-advisory-
- 502 <u>committee-immunization-addendum-guidance-use-covid-19-vaccines-fall-</u>
- 503 <u>2023/statement.pdf</u>. Accessed September 14, 2023.
- 5043.Government of Canada. COVID-19 signs, symptoms and severity of disease: a clinician
- 505 guide. Updated June 1, 2022. <u>https://www.canada.ca/en/public-</u>
- 506 health/services/diseases/2019-novel-coronavirus-infection/guidance-documents/signs-
- 507 <u>symptoms-severity.html#a3</u>. Accessed September 14, 2023.
- 508 4. Bertini CD, Jr., Khawaja F, Sheshadri A. Coronavirus Disease-2019 in the
 509 Immunocompromised Host. *Clin Chest Med.* 2023;44(2):395-406.
- 5. Public Health Agency of Canada. Canadian Immunization Guide. COVID-19 vaccines.
- 511 https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-
- 512 <u>immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html</u>. Updated
- 513 September 12, 2023. Accessed September 14, 2023.
- 514 6. Antinori A, Bausch-Jurken M. The Burden of COVID-19 in the Immunocompromised
- 515 Patient: Implications for Vaccination and Needs for the Future. *J Infect Dis.*516 2023;228(Suppl 1):S4-s12.

Singson JRC, Kirley PD, Pham H, et al. Factors Associated with Severe Outcomes Among
 Immunocompromised Adults Hospitalized for COVID-19 - COVID-NET, 10 States, March
 2020-February 2022. *MMWR Morbidity and mortality weekly report.* 2022;71(27):878-884.

- Turtle L, Thorpe M, Drake TM, et al. Outcome of COVID-19 in hospitalised
 immunocompromised patients: An analysis of the WHO ISARIC CCP-UK prospective
 cohort study. *PLoS Med.* 2023;20(1):e1004086.
- 523 9. Bahremand T, Yao JA, Mill C, Piszczek J, Grant JM, Smolina K. COVID-19
 524 hospitalisations in immunocompromised individuals in the Omicron era: a population525 based observational study using surveillance data in British Columbia, Canada. *The*526 *Lancet Regional Health Americas.* 2023;20:100461.
- Tseng H, Ackerson BK, Sy LS, et al., Effectiveness of mRNA-1273 bivalent (Original and
 Omicron BA.4/BA.5) COVID-19 vaccine in preventing hospitalizations for COVID-19,
 medically attended SARS-CoV-2 infections, and hospital death in the United States.
 medRXiv. 2023.
- 531 11. Nguyen VH BC, Bogdanov A, et al. Relative effectiveness of BNT162b2, mRNA-1273,
 532 and Ad26.COV2.S vaccines and homologous boosting in preventing COVID-19 in adults
 533 in the US. *medRxiv.* 2023.
- 534 12. Ono S, Michihata N, Yamana H, et al. Comparative Effectiveness of BNT162b2 and
 535 mRNA-1273 Booster Dose After BNT162b2 Primary Vaccination Against the Omicron
 536 Variants: A Retrospective Cohort Study Using Large-Scale Population-Based Registries
 537 in Japan. *Clin Infect Dis.* 2023;76(1):18-24.
- 538 13. Mayr FB TV, Shaikh OS, et al., Comparative COVID-19 Vaccine Effectiveness Over Time
 539 in Veterans. *Open Forum Infect Dis.* 2022;9(7).

- 540 14. Hulme WJ, Horne EMF, Parker EPK, et al. Comparative effectiveness of BNT162b2
 541 versus mRNA-1273 covid-19 vaccine boosting in England: matched cohort study in
 542 OpenSAFELY-TPP. *BMJ.* 2023;380:e072808.
- 543 15. Kopel H, Nguyen VH, Boileau C, et al. (in press.) Comparative effectiveness of Bivalent
 544 (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and
 545 BNT162b2 Bivalent Vaccine in Adults in the US. *Vaccines*.
- 546 16. Moderna Inc. SPIKEVAX (mRNA-1273) Full Prescribing Information. 2022.
- 547 17. Pfizer/BioNTech. COMIRNATY (BNT162b2) Full Prescribing Information. 2022.
- 548 18. Moderna Inc. Fact sheet for healthcare providers administering vaccine: emergency use
- 549 authorization of Moderna Covid-19 vaccine, bivalent (original and omicron ba.4/ba.5).
- 550 Moderna, Inc. <u>https://eua.modernatx.com/covid19vaccine-eua/eua-fact-sheet-</u>
 551 <u>providers.pdf</u>. Accessed August 25, 2023.
- 55219.Pfizer/BioNTech. Fact sheet for healthcare providers administering vaccine: emergency553use authorization (EUA): Pfizer-BioNTech COVID-19 vaccine, bivalent (original and
- 554 omicron BA.4/BA.5) and booster dose for 12 years of age and older (2022).
- 555 Pfizer/BioNTech. <u>https://www.fda.gov/media/167211/download</u>. Accessed March 7, 2023.
- 556 20. Wang X, Haeussler K, Spellman A, et al. Comparative effectiveness of mRNA-1273 and
 557 BNT162b2 COVID-19 vaccines in immunocompromised individuals: a systematic review
- and meta-analysis using the GRADE framework. *Frontiers in Immunology.* 2023;14.
- 559 21. Government of Canada. Health Canada authorizes Moderna COVID-19 vaccine targeting
- the Omicron XBB.1.5 subvariant. September 12, 2023. <u>https://www.canada.ca/en/health-</u>
- 561 <u>canada/news/2023/09/health-canada-authorizes-moderna-covid-19-vaccine-targeting-</u>
- 562 <u>the-omicron-xbb15-subvariant.html</u>. . Accessed September 14, 2023.
- 563 22. Health Canada. Health Canada authorizes Pfizer-BioNTech COVID-19 vaccine targeting
- 564 the Omnicron XBB.1.5 subvariant. https://www.canada.ca/en/health-

- 565 canada/news/2023/09/health-canada-authorizes-pfizer-biontech-covid-19-vaccine-566 targeting-the-omicron-xbb15-subvariant.html. Accessed September 29, 2023. Government of Canada. COVID-19 vaccines; Canadian immunization guide. Last partial 567 23. 568 2023. https://www.canada.ca/en/publiccontent update: June 27, 569 health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-570 vaccines/page-26-covid-19-vaccine.html#a6.4.considerations. Accessed September 14, 571 2023. Institute for Clinical Evaluative Sciences (ICES). ICES COVID-19 Dashboard. Vaccine 572 24. 573 Coverage by Priority Groups. Accessed August 22, 2023. 574 25. Public Health Agency of Canada. COVID-19 vaccination: Vaccination coverage. 575 https://health-infobase.canada.ca/covid-19/vaccination-coverage/. Accessed August 22, 576 2023. 577 26. Public Health Agency of Canada. Seasonal Influenza Vaccination Coverage in Canada, 578 2021-2022. https://www.canada.ca/en/public-health/services/immunization-579 vaccines/vaccination-coverage/seasonal-influenza-survey-results-2021-2022/full-580 report.html. Published 2023. Accessed September 18, 2023. 581 27. Harpaz R, Dahl RM, Dooling KL. Prevalence of Immunosuppression Among US Adults, 582 2013. JAMA. 2016;316(23):2547-2548. 583 28. Statistics Canada. Health-related concerns and precautions during the COVID-19 584 pandemic: a comparison of Canadians with and without underlying health concerns. July 585 2, 2020. https://www150.statcan.gc.ca/n1/en/pub/82-003-x/2020005/article/00001-586 eng.pdf?st=fRIC98Ej. Accessed April 21, 2023.
- 587 29. Public Health Agency of Canada. COVID-19 epidemiology update: Current situation.
- 588 Hospital use. September 2022-August 2023. https://health-infobase.canada.ca/covid-
- 589 <u>19/current-situation.html#graphHospVentICU</u>. Accessed September 5, 2023.

- 590 30. Pratama NR, Wafa IA, Budi DS, et al. Effectiveness of COVID-19 Vaccines against SARS-
- 591 CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta592 Regression. *Vaccines*. 2022;10(12):2180.
- 593 31. Higdon MM, Baidya A, Walter KK, et al. Duration of effectiveness of vaccination against
 594 COVID-19 caused by the omicron variant. *The Lancet Infectious diseases.*595 2022;22(8):1114-1116.
- 596 32. Public Health Ontario. Ontario Respiratory Virus Tool.
 597 <u>https://www.publichealthontario.ca/en/Data-and-Analysis/Infectious-Disease/Respiratory-</u>
 598 Virus-Tool. Accessed September 13, 2023.
- 599 33. Government of Canada. COVID-19 vaccination: doses administered. <u>https://health-</u>
 600 <u>infobase.canada.ca/covid-19/vaccine-administration/</u>. Published 2023. Accessed July 20,
 601 2023, 2023.
- 602 34. Public Health Agency of Canada. COVID-19 epidemiology update: current situation.
 603 Cases and hospitalizations July December 2020. <u>https://health-</u>
 604 <u>infobase.canada.ca/covid-19/current-situation.html#graphHospVentICU</u>. Accessed April
 605 27, 2023.
- Wang L, Berger N, Kaelber D, Davis P, Volkow N, Xu R. COVID infection rates, clinical
 outcomes, and racial/ethnic and gender disparities before and after Omicron emerged in
 the US. *medRxiv.* 2022;2022.02.21.22271300.
- 609 36. Public Health Agency of Canada. COVID-19 epidemiology update: Current situation:
- National and regional trends. <u>https://health-infobase.canada.ca/covid-19/current-</u>
 <u>situation.html#graphHospVentICU</u>. Accessed September 5, 2023.
- 612 37. McNaughton CD, Austin PC, Sivaswamy A, et al. Post-acute health care burden after
 613 SARS-CoV-2 infection: a retrospective cohort study. *Cmaj.* 2022;194(40):E1368-e1376.

614	38.	Statistics Canada. Consumer Price Index, annual average, not seasonally adjusted. Table
615		19-10-0005-01. <u>https://www150.statcan.gc.ca/t1/tbl1/en/cv.action?pid=1810000501</u> .
616		Accessed April 26, 2023.
617	39.	Ontario Ministry of Health. Schedule of Benefits. Physician Services Under the Health
618		Insurance Act (June 29, 2023 (effective July 24, 2023)).
619		https://health.gov.on.ca/en/pro/programs/ohip/sob/physserv/sob_master.pdf. Accessed
620		September 5, 2023.
621	40.	Government of Alberta. Alberta Interactive Health Data Application. Hospital
622		Ambulatpopry Care Case Costs - CACS - 2019 version. Acute upper respiratory.
623		http://www.ahw.gov.ab.ca/IHDA_Retrieval/selectSubCategoryParameters.do. Accessed
624		April 23, 2023.
625	41.	Huang BZ, Creekmur B, Yoo MS, Broder B, Subject C, Sharp AL. Healthcare Utilization
626		Among Patients Diagnosed with COVID-19 in a Large Integrated Health System. J Gen
627		Intern Med. 2022;37(4):830-837.
628	42.	Canadian Institute for Health Information. COVID-19 hospitalization and emergency
629		department statistics. https://www.cihi.ca/en/covid-19-hospitalization-and-emergency-
630		department-statistics. Accessed April 18, 2023.
631	43.	Canadian institute for Health Information. Trends in Hospital Spending, 2005-2006 to

632 2020-2021 - Data Tables - Series C: Average Direct Cost per Patient by Selected

633 Functional Centre. <u>https://www.cihi.ca/en/trends-in-hospital-spending-2005-2006-to-</u>

- 634 <u>2020-2021-data-tables-series-c-average-direct-cost-per</u>. Accessed April 26, 2023.
- 635 44. Smith KJ, Roberts MS. Cost-effectiveness of newer treatment strategies for influenza. *The*636 *American journal of medicine.* 2002;113(4):300-307.

637	45.	Centers for Disea	se Control and Prevention. Isolation and Precautions for People with
638		COVID-19.	https://www.cdc.gov/coronavirus/2019-ncov/your-health/isolation.html.
639		Accessed Decemb	per 21, 2022.

- 640 46. Barbut F, Galperine T, Vanhems P, et al. Quality of life and utility decrement associated
 641 with Clostridium difficile infection in a French hospital setting. *Health and quality of life*642 *outcomes.* 2019;17(1):6.
- 643 47. Di Fusco M, Shea KM, Lin J, et al. Health outcomes and economic burden of hospitalized
 644 COVID-19 patients in the United States. *J Med Econ.* 2021;24(1):308-317.
- 645 48. Sandmann FG, Tessier E, Lacy J, et al. Long-Term Health-Related Quality of Life in Non646 Hospitalized Coronavirus Disease 2019 (COVID-19) Cases With Confirmed Severe Acute

647

Analysis and Cross-Sectional Comparison With Controls. *Clin Infect Dis.*2022;75(1):e962-e973.

Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in England: Longitudinal

- The PHOSP-COVID Collaborative Group. Clinical characteristics with inflammation
 profiling of long COVID and association with 1-year recovery following hospitalisation in
 the UK: a prospective observational study. *Lancet Respir Med.* 2022;10:761-775.
- 50. Statistics Canada. Table 13-10-0837-01. Life expectancy and other elements of the
 complete life table, single-year estimates, Canada, all provinces except Prince Edward
 Island. https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310083701. Accessed
 September 8, 2023.
- 657 51. Guertin JR, Feeny D, Tarride JE. Age- and sex-specific Canadian utility norms, based on
 658 the 2013-2014 Canadian Community Health Survey. *Cmaj.* 2018;190(6):E155-e161.
- 659 52. CADTH. Guidelines for the economic evaluation of health technologies: Canada. Ottawa660 March 2017.

- 661 53. WHO guide for standardization of economic evaluations of immunization programmes,662 2nd edition. Geneva: World Health Organization; 2019.
- 663 54. Public Health Agency of Canada. National Advisory Committee on Immunization (NACI)
 664 Guidelines for the Economic Evaluation of Vaccination Programs in Canada. April 2023.
- 665 55. FDA U.S. Food & Drug Administration. Vaccines and Related Biological Products Advisory
- 666 Committee. Moderna COVID-19 Variant Vaccines. Moderna, Inc. June 15, 2023.
 667 <u>https://www.fda.gov/media/169539/download</u>. Accessed October 10, 2023.
- 668 56. Kohli M, Maschio M, Joshi K, et al. (in press) The potential clinical impact and cost669 effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States.
 670 *Journal of Medical Economics*.
- 671 57. Breznik JA, Rahim A, Kajaks T, et al. Protection from Omicron Infection in Residents of
 672 Nursing and Retirement Homes in Ontario, Canada. *J Am Med Dir Assoc.* 2023;24(5):753673 758.
- 674 58. Cochrane UK. Meta-analysis: what, why and how. <u>https://uk.cochrane.org/news/meta-</u>
 675 <u>analysis-what-why-and-how</u>. Accessed October 11, 2023.
- 676 59. Cromer D, Steain M, Reynaldi A, et al. Predicting vaccine effectiveness against severe
 677 COVID-19 over time and against variants: a meta-analysis. *Nat Commun.*678 2023;14(1):1633.
- 679 60. Cromer D, Steain M, Reynaldi A, et al. Neutralising antibody titres as predictors of
 680 protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis.
 681 *Lancet Microbe.* 2022;3(1):e52-e61.
- 682 61. Ferdinands JM, Rao S, Dixon BE, et al. Waning of vaccine effectiveness against moderate
 683 and severe covid-19 among adults in the US from the VISION network: test negative,
 684 case-control study. *BMJ.* 2022;379:e072141.

- 685 62. Zurovac J, Barna M. mRNA-1273 vaccinated expenditure of hospitalisation analysis
 686 results. 03NOV2023. Moderna data on file.
- 687 63. Saskatchewan Ministry of Health. COVID-19 Vaccine Guidance.
- 688 https://www.health.gov.on.ca/en/pro/programs/publichealth/coronavirus/docs/vaccine/C
- 689 OVID-19_vaccine_administration.pdf. Published 2023. Updated October 6, 2023. Accessed
- 690 October 19, 2023.

691 **Declarations**

- 692 Ethics approval and consent to participate: Not applicable
- 693 Consent for publication: Not applicable
- 694 Availability of data and materials: The datasets used and/or analyzed during the current study
- are available from the corresponding author on reasonable request.
- 696 Competing interests: EB, KaJ, KeJ, and NV are employees of Moderna, Inc and may hold
- shares and stock options in Moderna, Inc. MK is a shareholder in Quadrant Health Economics,
- 698 Inc., which was contracted by Moderna, Inc. to conduct this study. KF, AL, and MM are
- 699 consultants at Quadrant Health Economics Inc.
- Funding: This study was funded by Moderna, Inc., Cambridge, MA, USA.
- Authors' contributions: Conceptualization, AL, MK, MM, KaJ, NV; Methodology, AL, KaJ, MK,
- 702 MM, EB, and NV; Software, MM; Validation, AL and MK; Formal Analysis, AL and KF; Writing –
- 703 Original Draft Preparation, AL and MK; Writing Review & Editing, KaJ, KeJ, EB, NV; Funding
- 704 Acquisition, KaJ, EB, NV
- 705 Acknowledgements: Not applicable
- 706 Author's information (optional): Not applicable